Wei Zexi accepted treatment for 16 years before the United States eliminated Wei XI | | | treatment _ cancer immune therapy methods news
Reporter Cao Xueping Beijing
Xidian University computer science student Wei Zexi, living through Baidu search to find hospitals of armed police corps in Beijing, accepted a so-called tumor immune therapy--DC-CIK therapy treatment, cost more than 200,000 yuan, also died.
On May 2, the chief scientist Dr Zhou Xiangjun cell medical technology limited Shenzhen source told the China business newspaper, said in an interview, "were involved in the death of the West the CIK, DC-CIK, this is the United States in 2000 on obsolete technology. Obsolete technical reason CIK is free of tumor-specific t-cells, clinical trial found no effect. ”
In fact, at present, the tumor cell immunotherapy technology does not get national health and clinical application of family planning Commission "zhunsheng Zheng", this technology was only a limited clinical study category, after Director of the Ministry of health has approved only a partial immune cell therapy clinical trial in hospital.
According to Zhou Xiangjun introduced, tumor immune treatment real of turning point is 2010 before and after, to b lymphatic leukemia CD19 CAR-T treatment, late recurrence melanin tumor of CTLA-4 antibody and PD-1 antibody treatment of excellent effect for logo, academia and medical Territories finally understanding and accept such a medical phenomenon: patients body if has enough more of tumor special specific t cell, is has may completely clear body of tumor cell to extended patients life of. While, with Yu II generation measuring sequence technology on variety tumor of full outside explicit child or full gene group measuring therapy, also understand has why reputation are long of target to drug only extended in the bit survival period not change five years survival rate: because all target to drug, tumor because height mutation and exists anti-target to drug of resistance drug Asia clone cell, in target to drug using Hou resistance drug Asia clone cell not by effect and led to tumor soon recurrence.
"After foreign drug companies, Pfizer, Merck, Bristol-Myers to Novartis, GSK, have targeted treatment programs in the hands of, and fully turned to the development of cancer immunotherapy, including a variety of immune inhibitors of checkpoint, tumor-specific t cell-specific TIL, MASCT, CAR-T, TCR-T. In recent years, the AACR and ASCO Conference report will know.?"Zhou Xiangjun said. According to press reports, Zhou Xiangjun and Dr Henry source (Shanghai) biotechnology co, Chief Scientist, Shanghai Jiao Tong University School of pharmacy, Molecular Pharmacology Professor, visiting professor. United States Stanford University School of medicine cell biology post-doctoral, doctor of medicine, medical school, University of Hawaii; more than 20 articles and research papers in Science, JCI, published in JBC.
Responsible editor: Liu Debin SN222
Article keywords:Wei Zexi tumor immune therapy treatment
I want feedback
Save a Web page
China business
魏则西所接受治疗方法16年前被美国淘汰|魏则西|肿瘤生物免疫治疗方法|治疗方法_新闻资讯
本报记者 曹学平 北京报道
西安电子科技大学计算机专业学生魏则西，生前通过百度搜索找到武警北京总队第二医院，接受一种号称为肿瘤生物免疫治疗方法——DC-CIK疗法的治疗，在耗费20多万元后，还是不幸去世 。
5月2日，深圳源正细胞医疗技术有限公司首席科学家周向军博士在接受《中国经营报》记者采访时表示，“则西之死中涉及的CIK， DC-CIK，这是美国2000年就淘汰的技术。淘汰的技术原因是CIK不含肿瘤特异性T细胞，临床试验没有发现治疗效果。”
事实上，目前，肿瘤细胞免疫治疗技术并未获得国家卫生和计划生育委员会临床应用的“准生证”，该技术仅被限定在临床研究范畴；此前，仅总后卫生部曾经批准部分医院开展免疫细胞治疗临床应用试点。
据周向军介绍，肿瘤免疫治疗真正的转折点是2010年前后，以B淋巴白血病CD19 CAR-T治疗，晚期复发黑色素瘤的CTLA-4抗体和PD-1抗 体治疗的优异疗效为标志，学术界和医学界终于理解和接受这样一种医学现象：患者体内如果有足够多的肿瘤特异性T细胞，是有可能完全清除体内的肿瘤细胞从而 延长患者生命的。同时，借助于二代测序技术对多种肿瘤的全外显子或全基因组测疗，也明白了为什么名声正隆的靶向药只延长中位生存期不改变五年生存率：因为 所有靶向药，肿瘤因为高度突变而存在抗靶向药的耐药亚克隆细胞，在靶向药使用后耐药亚克隆细胞不受影响而导致肿瘤很快复发。
“在此之后 国外大药企，从辉瑞，默沙东，施贵宝到诺华GSK， 纷纷处理手上的靶向治疗项目，而全力转向肿瘤免疫治疗开发，包括各种不同免疫检查点抑制剂，肿瘤特异 性T细胞如特异性TIL， MASCT， CAR-T， TCR-T。 这从近几年的AACR和ASCO会议的报告内容就知道了。” 周向军说。 据记者 了解，周向军博士现兼恒瑞源正（上海）生物技术有限公司首席科学家、上海交通大学药学院分子药理学教授、客座教授。美国斯坦福大学医学院细胞生物学博士 后，夏威夷大学医学院生物医学博士；二十多篇科研论文在Science， JCI， JBC等杂志发表。
责任编辑：刘德宾 SN222
文章关键词： 魏则西 肿瘤生物免疫治疗方法 治疗方法
我要反馈
保存网页
中国经营报
